Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the enzymatic activity of COX2, and inhibitors of COX2 suppress the growth of prostate cancer cells in vitro as well as prostate tumorigenesis in vivo (Liu et al, 2000; Gupta et al, 2004; Patel et al, 2005; Narayanan et al, 2006). Here, PTGS2 is linked to prostate cancer.